Filing Summary
Entity and period: The supplied filing is Cortexyme, Inc.’s Form 10-Q for the quarter ended March 31, 2020—not a Quince Therapeutics filing. The filing describes Cortexyme as a clinical-stage biopharmaceutical company developing COR388 and other candidates. Financial amounts below are in millions unless stated otherwise.
Financial Performance and Position
- Revenue: No revenue was reported; the company is clinical-stage. Gross margin is not applicable.
- Expenses and loss: Research and development expense was $14.4 million versus $4.8 million in Q1 2019; general and administrative expense was $3.5 million versus $1.3 million. Operating loss was $17.9 million, and net loss was $17.2 million, compared with $5.7 million in the prior-year quarter. Basic and diluted loss per share was $0.61 versus $1.61; the share count increased substantially after the 2019 IPO.
- Cash flow: Operating cash use was $10.8 million versus $7.2 million. Investing cash use was $72.7 million, largely reflecting purchases of securities; financing provided $117.9 million, primarily from the February 2020 private placement. Cash and cash equivalents rose to $85.6 million from $51.2 million at year-end.
- Liquidity and capital: Short-term investments were $76.8 million and long-term investments $61.1 million. Cash, cash equivalents and short-term investments totaled approximately $162.4 million; total cash, cash equivalents and investments were approximately $223.6 million. The company raised $125.0 million gross, or $117.7 million net, in a PIPE by issuing 2.5 million shares at $50 per share.
- Debt and liabilities: No borrowings are reported. Total liabilities were $13.2 million, including $0.1 million of operating lease liabilities. The filing reports an accumulated deficit of $87.0 million.
Period Changes and Management Commentary
- R&D expense rose 198%, mainly due to COR388 Phase 2/3 trial costs, manufacturing, and increased personnel. G&A expense increased 178%, reflecting headcount, public-company costs, insurance, and professional fees.
- Management said existing resources were expected to fund planned operations through 2022, including completion and announcement of GAIN trial top-line results. The liquidity note separately states cash, cash equivalents, and short-term investments were expected to fund operations for at least 12 months from issuance of the statements.
- The GAIN global Phase 2/3 trial of COR388 for mild-to-moderate Alzheimer’s disease was ongoing. The company planned an interim analysis by year-end 2020 after approximately 100 patients in each of three arms completed six months of treatment, and expected top-line results by year-end 2021.
Outlook, Risks, and Unusual Items
- Management expected R&D and G&A spending to increase as clinical development, manufacturing, staffing, and public-company costs continue. The company expects ongoing operating losses and may seek additional capital; future financing could dilute shareholders or impose debt restrictions.
- COVID-19 had not, as of the filing, changed stated GAIN analysis timelines; trial screening, randomization, and an open-label extension were continuing. Management reported drug supply on hand for the full GAIN trial and no significant supply disruptions at that time, while warning that the pandemic could affect enrollment, trial completion, suppliers, operations, and financing access.
- The investment portfolio included corporate debt securities subject to credit downgrades or impairment. Management said it expected to hold securities to maturity, but noted potential losses and lower investment yields.
- The PIPE included a $1.5 million purchase by an entity affiliated with a board member. No material legal proceedings were reported. Disclosure controls were deemed effective.
Important Facts to Verify
- Confirm the intended issuer: the supplied filing names Cortexyme, Inc., while the request identifies Quince Therapeutics, Inc.
- Reconcile runway statements: the filing gives both “at least 12 months” and funding through 2022; review the assumptions behind the longer estimate.
- Confirm liquidity figures and classifications: approximately $162.4 million of cash, cash equivalents, and short-term investments versus approximately $223.6 million including long-term investments.
- Monitor whether COVID-19 or other factors altered GAIN trial enrollment, interim-analysis timing, completion, or top-line results expectations.
- Assess future cash burn, investment-credit exposure, and potential dilution if additional financing is needed.